Oncology

Mutations in HER2, also known as ERBB2, represent a distinct molecular subset of NSCLC, occurring in approximately 2–4% of cases, and are…

EpNECs are considered rare and are often associated with a poor prognosis, with up to 85% of patients presenting with advanced…

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage, when most patients have underlying cirrhosis. Prognosis is…

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, characterized by the…

Despite improved screening and treatment in developing nations, cervical cancer continues to have a global incidence of approximately…

Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms that originate from cells of the diffuse neuroendocrine system…

Liver cancer is a leading global health concern, ranking as the sixth most common cancer and the third deadliest in 2022, with over…

New analysis reveals nivolumab’s impact on disease-free survival in high-risk muscle-invasive bladder cancer.